Abstract Details

Title Evaluating Hippocampal Volumetric Reliability Across Software Versions of Portable Low-Field FLAIR MRI

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P2 - Poster Session 2 (11:45 AM-12:45 PM)

Poster/Presentation
Number 13-013

Objective To quantify the impact of successive software versions on hippocampal volumetric reliability in portable low-field MRI (pMRI), relative to conventional MRI (cMRI).

Background pMRI systems operating at 0.064 Tesla have undergone multiple software updates that may influence the accuracy of hippocampal volumetric measurements, a quantitative marker of neurodegenerative progression and postoperative recovery outcomes. Given these software updates, evaluating their impact on volumetric consistency is essential for validating pMRI in clinical contexts.

Design/Methods We analyzed 178 paired pMRI and cMRI scans obtained between 2018 and 2022, each acquired within 24 hours of one another using FLAIR sequences. Hippocampal volumes were segmented automatically using WMH-SynthSeg, and results were grouped by software version (8.1, 8.2, 8.3). Percent differences in hippocampal volumes between pMRI and cMRI, Pearson correlation coefficients, and one-way ANOVA were utilized to evaluate volumetric reliability across versions.

Results Across software versions, mean hippocampal bias between pMRI and cMRI remained consistent (F(2,175)=0.82, p=0.44): –8.0 ± 18.1%, –8.8 ± 14.0%, and –11.3 ± 10.4% for versions 8.1, 8.2, and 8.3, respectively, with pMRI consistently underestimating hippocampal volumes by roughly 10%. Variability of the pMRI-cMRI volume differences decreased substantially across software versions (8.1: 328.79 mm³; 8.2: 197.18 mm³; 8.3: 107.28 mm³). There was no significant correlation between hippocampal volumes measured on pMRI and cMRI in version 8.1 (r = -0.17, p > 0.05), while strong positive correlations emerged in versions 8.2 (r = 0.62, p < 0.001) and 8.3 (r = 0.59, p < 0.001), demonstrating improved agreement between pMRI and cMRI measurements in newer software versions.

Conclusions Successive pMRI software updates substantially improved hippocampal volumetric reliability relative to cMRI. These findings underscore that continued software refinement enhances the quantitative accuracy of portable low-field MRI, advancing its clinical applicability for monitoring neurodegenerative changes.

Authors/Disclosures
Steph Maynez PRESENTER	Ms. Maynez has nothing to disclose.
Annabelle Shanks, BS	Ms. Shanks has nothing to disclose.
Hailey Brigger	Ms. Brigger has nothing to disclose.
Ian P. Johnson	Mr. Johnson has nothing to disclose.
Alison Champagne	Mrs. Champagne has nothing to disclose.
Rachel Hird	Ms. Hird has nothing to disclose.
Gordon Sze	Gordon Sze has nothing to disclose.
Jua Iglesias Gonzalez (Martinos Center for Biomedical Imaging)	Jua Iglesias Gonzalez has nothing to disclose.
Adam De Havenon, MD, FAAN (Yale University)	Dr. De Havenon has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novo Nordisk. Dr. De Havenon has or had stock in Certus.Dr. De Havenon has or had stock in TitinKM. The institution of Dr. De Havenon has received research support from NIH/NINDS. Dr. De Havenon has received publishing royalties from a publication relating to health care.
Kevin N. Sheth, MD, FAAN (Yale UniversityDivision of Neuro and Critical Care)	Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Sheth has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NControl. Dr. Sheth has received stock or an ownership interest from Astrocyte. Dr. Sheth has received stock or an ownership interest from Alva. The institution of Dr. Sheth has received research support from Biogen. The institution of Dr. Sheth has received research support from Novartis. The institution of Dr. Sheth has received research support from Bard. The institution of Dr. Sheth has received research support from Hyperfine. Dr. Sheth has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��